Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
53.62
-0.39 (-0.72%)
Nov 19, 2024, 4:00 PM EST - Market closed
Keros Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | 0.65 | 0.15 | - | 20.1 | - | 10 | Upgrade
|
| Revenue Growth (YoY) | 8037.50% | - | - | - | - | 0% | Upgrade
|
| Cost of Revenue | 165.49 | 135.26 | 87.27 | 55.14 | 33.86 | 17.38 | Upgrade
|
| Gross Profit | -164.84 | -135.11 | -87.27 | -35.04 | -33.86 | -7.38 | Upgrade
|
| Selling, General & Admin | 39.19 | 34.83 | 27.53 | 21.33 | 12.8 | 3.18 | Upgrade
|
| Operating Expenses | 39.19 | 34.83 | 27.53 | 21.33 | 12.8 | 3.18 | Upgrade
|
| Operating Income | -204.03 | -169.94 | -114.79 | -56.37 | -46.66 | -10.56 | Upgrade
|
| Interest Expense | - | - | -0 | -0 | -0.01 | -0.01 | Upgrade
|
| Interest & Investment Income | 20.73 | 14.76 | 3.64 | 0.03 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.76 | -0.3 | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 2.49 | 2.49 | 6.47 | -0.38 | 1.13 | -1.77 | Upgrade
|
| Pretax Income | -181.57 | -152.99 | -104.68 | -56.73 | -45.53 | -12.34 | Upgrade
|
| Income Tax Expense | - | - | - | 2.01 | -0.17 | - | Upgrade
|
| Net Income | -181.57 | -152.99 | -104.68 | -58.74 | -45.36 | -12.34 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 1.8 | Upgrade
|
| Net Income to Common | -181.57 | -152.99 | -104.68 | -58.74 | -45.36 | -14.14 | Upgrade
|
| Shares Outstanding (Basic) | 35 | 29 | 25 | 23 | 16 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 35 | 29 | 25 | 23 | 16 | 2 | Upgrade
|
| Shares Change (YoY) | 21.32% | 16.66% | 8.17% | 50.48% | 566.41% | -50.70% | Upgrade
|
| EPS (Basic) | -5.21 | -5.20 | -4.15 | -2.52 | -2.93 | -6.08 | Upgrade
|
| EPS (Diluted) | -5.21 | -5.20 | -4.15 | -2.52 | -2.93 | -6.08 | Upgrade
|
| Free Cash Flow | -142.5 | -126.97 | -71.3 | -63.17 | -37.19 | -16.27 | Upgrade
|
| Free Cash Flow Per Share | -4.09 | -4.31 | -2.82 | -2.71 | -2.40 | -6.99 | Upgrade
|
| Gross Margin | - | - | - | -174.34% | - | -73.79% | Upgrade
|
| Operating Margin | -31341.63% | -112543.71% | - | -280.46% | - | -105.63% | Upgrade
|
| Profit Margin | -27890.94% | -101319.21% | - | -292.26% | - | -141.36% | Upgrade
|
| Free Cash Flow Margin | -21889.86% | -84087.42% | - | -314.29% | - | -162.69% | Upgrade
|
| EBITDA | -202.89 | -169.13 | -114.12 | -56 | -46.38 | -10.36 | Upgrade
|
| EBITDA Margin | - | - | - | -278.58% | - | -103.55% | Upgrade
|
| D&A For EBITDA | 1.14 | 0.82 | 0.67 | 0.38 | 0.28 | 0.21 | Upgrade
|
| EBIT | -204.03 | -169.94 | -114.79 | -56.37 | -46.66 | -10.56 | Upgrade
|
| EBIT Margin | - | - | - | -280.46% | - | -105.63% | Upgrade
|
| Revenue as Reported | 0.65 | 0.15 | - | 20.1 | - | 10 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.